Deep Brain Stimulation and Alzheimer’s Disease: A Look at the Research Studies

May 26, 2022Neelem Sheikh

Deep brain stimulation, or DBS, is a neurosurgical technique that aims to regulate neuron activity via internal pulse generators to electrodes in specific target areas within the brain. The development of deep brain stimulation is largely attributed to Alim Benabid, who was utilizing surgical approaches to treat cases of Parkinson’s disease, dystonia, and several psychiatric conditions that had historically failed to respond to drug-based therapies.

Deep brain stimulation has since shown great promise for treating movement disorders associated with neurological diseases, such as Parkinson’s disease and essential tremor, and consequently is widely used in the field of neurological diseases.

More recently, researchers have begun investigating deep brain stimulation and Alzheimer’s disease. Below, we take a closer look at deep brain stimulation and Alzheimer’s disease, address the limitations of existing research, and propose a new gold standard for measuring therapeutic response.

How Is Deep Brain Stimulation Performed?

In general, deep brain stimulations systems have three main components:

  • A neurostimulator: A programmable battery-powered, pacemaker-like device that creates electric pulses and is surgically implanted under the skin of the chest
  • A lead: A coated wire with electrodes at the tip to deliver the electric pulses to brain tissue that is strategically and precisely placed inside the brain
  • An extension: An insulated wire connecting the lead to the neurostimulator device that is placed under the skin, running from the scalp, behind the ear, down the neck, and into the chest

Whether performed using traditional approaches or robotically, deep brain stimulation is typically performed in three distinct stages:

  1. Imaging and placement of bone markers/screws 
  2. Placement of electrodes
  3. Placement of the battery and lead extender

Deep Brain Stimulation and Alzheimer’s Disease: Animal Studies

Over the past decade, deep brain stimulation has shown several positive effects in animal models, demonstrating benefits such as enhanced short- and long-term memory, restoration of spatial memory-related functions, decreased amyloidosis, and decreased neuronal loss in the cortex and hippocampus. Animal studies have incorporated multiple stimulation targets, such as the midline thalamic nuclei (MTN), the intralaminar thalamic nucleus (ILN), the anterior nucleus of thalamus (ANT), the hippocampal CA1 subfield, and the entorhinal cortex (EC).

Deep Brain Stimulation and Alzheimer’s Disease: Human Studies

During this same time, deep brain stimulation has been investigated in several human clinical studies. Here is a look at some of the findings:

  • A 2010 phase I trial demonstrated that after deep brain stimulation surgery, Alzheimer’s patients had improved memory, decreased rates of cognitive decline, and increased cerebral glucose metabolism.
  • A 2015 phase I trial showed that after one year of deep brain stimulation, Alzheimer’s patients showed decreased rates of hippocampal atrophy as well as stabilization of nutritional status.
  • A 2018 phase II trial found that participants under 65 showed similar rates of decline to controls (those without the neurostimulator device turned on), meaning there was no decrease in the rate of cognitive decline. However, participants over 65 showed decreased rates of cognitive decline compared to controls. This suggests that deep brain stimulation may not benefit individuals with early-onset Alzheimer’s disease (diagnosed under age 65) but may benefit those over 65. 

Stimulation targets in human studies involved the fornix, the nucleus basalis of Meynert (NBM), and the ventral capsule/ventral striatum (VC/VS).

The mechanism of action currently remains unclear; however, several potential mechanisms have been proposed, such as those listed below:

  • Regulation of neural networks
  • Reduction in beta-amyloid levels
  • Reduction in tau levels
  • Promotion of nerve oscillation
  • Reduction of neuroinflammation
  • Induction of nerve growth factor (NGF) synthesis
  • Regulation of the cholinergic system

Limitations of Research Surrounding Deep Brain Stimulation and Alzheimer’s Disease

Currently, to assess and measure therapeutic response to deep brain stimulation in clinical trials, studies rely on narrow-natured, simple cognitive assessments, such the Mini-Mental State Exam (MMSE) and the Clinical Dementia Rating (CDR).

Many of these traditional assessments are purely cognitive batteries that only assess a small subset of neurocognitive domains. Assessment of Activities of Daily Living (ADLs) is arguably the most relevant and robust measure of neurocognitive function. However, traditional cognitive function assessment tools are not ecologically valid, meaning the design of the evaluation does not match and align with neurocognitive states representative of Activities of Daily Living (ADLs). Because of these limitations, these assessments frequently produce noisy, highly variable results that lack the specificity and granularity to confidently draw conclusions about the efficacy of deep brain stimulation.

To improve our understanding of therapeutic response to deep brain stimulation, it is important to assess a breadth of both cognitive and functional domains at a highly granular level.

A New Gold Standard for Monitoring Therapeutic Response

At Altoida, we are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.

By completing a 10-minute series of augmented reality and motor activities designed to simulate complex Activities of Daily Living on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores. This data can be tracked longitudinally to reveal trends and patterns while flagging concerning ones.

Altoida is powering the next generation of clinical trials—our app-based medical device will provide researchers and pharmaceutical companies with the ability to increase cost efficiency, speed, and success of neurological disease clinical trials from subject screening to subject monitoring to data analysis. Our Precision Neurology platform and app-based medical device provide:

  • Cost-effective subject screening: Altoida will enable reliable precision diagnosis for subject screening and selection, conserving the use of expensive imaging. Our device can be used as an initial tool to narrow down the subject pool, filtering out ineligible subjects, before completing imaging or diagnostic procedures necessary for key inclusion criteria.
  • A robust proxy for traditional endpoints: Altoida will serve as a robust proxy to traditional endpoints in neurological disease clinical trials, providing highly sensitive, generalizable longitudinal data. 
  • Infrastructure for decentralized clinical trials: Altoida’s robust digital test platform, equipped with a connected ecosystem for communication with patients and full study management, provides all necessary components for seamless virtual testing and monitoring as well as statistical data analysis.

To learn more about deep brain stimulation and Alzheimer’s or about utilizing Altoida’s Precision Neurology platform for neurological disease research and clinical trials, contact us today.

Contact Us

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 

CONTACT@ALTOIDA.COM

Follow Us

Policy

By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.


Our Disclaimer

@ Altoida 2022